Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2016 · 10-Q
Revenue$3.32M$3.32M−90.9% vs Q3 2015 Net Income-$8.00M-$8.00MN/M vs Q3 2015 EPS Diluted-$43.97-$43.97N/M vs Q3 2015 Gross Profit$1,470,000+107.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,346,000N/M Margins · derivedGross margin44.3%+42.4 pt vs Q3 2015
Operating margin-195.7%−177.5 pt vs Q3 2015
Net margin-241.3%−226.6 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 17, 2016 · 48 d after period end